道格•福斯特

2023年7月10日,

Altis實驗室——計算成像公司加速臨床試驗與人工智能——最近宣布關閉其600萬美元的種子資金。和Benchstrength Debiopharm創新基金共同圓與參與戰略天使Doug培養包括數字醫療公司的前首席執行官Verana健康,和理查德Gliklich,醫學博士,真實數據公司的創始人兼首席執行官OM1。醫學成像占90%的醫療數據。的信念和Altis成立成像臨床資料最豐富的地區,但遠遠沒有得到充分利用。簡化的解釋指南開發40多年前被高估和低估的臨床效益,從而限製了臨床醫生的能力衡量癌症治療工作。在世界上最大的專有數據庫癌症成像和縱向臨床背景下,公司的最先進的深度學習模型預測臨床端點幫助量化治療效果超越簡單的和主觀的腫瘤大小的測量。資金將用於背板的發展規模,Altis”AI-powered成像生物標誌物的平台,在實體瘤類型和治療領域。和領先的生物製藥公司拜耳製藥使用背板來分析成像1 - 3期臨床試驗的數據更有意義。公司主機背板專有的預後模型雲平台為生物製藥研發團隊自動分析成像臨床試驗數據。和模型使研究人員更準確地預測分層患者基線和衡量治療效果的亞種。 These insights help sponsors generate higher quality evidence earlier in clinical development to increase success rates in late-stage trials and inform critical R&D decisions spanning go/no-go, trial design, reimbursement strategy, and revivals of shelved assets. Altis’ imaging-based prognostication (IPRO) technology was validated in collaboration with Canada’s leading cancer centers, with results published in the Journal of Clinical Oncology – Clinical Cancer Informatics and presented at the American Society of Clinical Oncology. KEY QUOTES: “We are thrilled to partner with Benchstrength and Debiopharm. This partnership will help us execute on our mission to reduce the excessive time and cost it takes to bring novel, effective treatments to patients in need.” — Felix Baldauf-Lenschen, Co-Founder and CEO of Altis “In R&D, imaging is a core component of what we do in clinical trials and current methods don’t exploit its full potential. We believe that AI-powered tools, such as those developed by Altis, will become the new standard for measuring clinical benefit not just in clinical trials, but also in clinical care.” — Carolina Haefliger, MD, Head of Translational Medicine at Debiopharm and Board Observer at Altis “It’s clear that AI will have a significant impact across healthcare, but Altis is uniquely positioned to transform the economics of clinical development. The Altis team has curated an unparalleled clinical imaging database in terms of both depth and breadth, which they are translating into actionable clinical insight thanks to their AI models.” — Kenneth Chenault, Managing Partner at Benchstrength and Board Director at Altis “This milestone for Altis is a testament to Canada’s leading role in both AI and clinical research. Our goal is to accelerate therapeutic development and improve the standard of care.” — Sally Daub, Co-Founder and Board Chair at Altis Trending on Pulse 2.0